TCMD Stock Overview
A medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Tactile Systems Technology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.85 |
| 52 Week High | US$17.90 |
| 52 Week Low | US$11.12 |
| Beta | 1.17 |
| 11 Month Change | 25.70% |
| 3 Month Change | 34.72% |
| 1 Year Change | 27.59% |
| 33 Year Change | -13.64% |
| 5 Year Change | -72.20% |
| Change since IPO | 61.10% |
Recent News & Updates
Recent updates
Tactile Systems Technology, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 07
Investors Holding Back On Tactile Systems Technology, Inc. (NASDAQ:TCMD)
Jul 17US$20.67: That's What Analysts Think Tactile Systems Technology, Inc. (NASDAQ:TCMD) Is Worth After Its Latest Results
May 09Tactile Systems Technology, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 23Does Tactile Systems Technology (NASDAQ:TCMD) Have A Healthy Balance Sheet?
Oct 10Capital Allocation Trends At Tactile Systems Technology (NASDAQ:TCMD) Aren't Ideal
Sep 16Is It Time To Consider Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Jul 13Are Investors Undervaluing Tactile Systems Technology, Inc. (NASDAQ:TCMD) By 26%?
May 10Is Tactile Systems Technology (NASDAQ:TCMD) Using Too Much Debt?
Feb 16Is Tactile Systems Technology (NASDAQ:TCMD) A Risky Investment?
Oct 12Tactile Systems Technology GAAP EPS of -$0.23 misses by $0.09, revenue of $59.6M beats by $2.72M
Aug 01Is Tactile Systems Technology (NASDAQ:TCMD) A Risky Investment?
Jun 14Investors Could Be Concerned With Tactile Systems Technology's (NASDAQ:TCMD) Returns On Capital
Jan 20Some Investors May Be Worried About Tactile Systems Technology's (NASDAQ:TCMD) Returns On Capital
May 20Shareholder Returns
| TCMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 14.0% | 1.5% | 2.2% |
| 1Y | 27.6% | 20.9% | 31.7% |
Return vs Industry: TCMD exceeded the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: TCMD underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| TCMD volatility | |
|---|---|
| TCMD Average Weekly Movement | 6.9% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TCMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TCMD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 992 | Sheri Dodd | tactilemedical.com |
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders.
Tactile Systems Technology, Inc. Fundamentals Summary
| TCMD fundamental statistics | |
|---|---|
| Market cap | US$428.35m |
| Earnings (TTM) | US$15.45m |
| Revenue (TTM) | US$285.05m |
27.7x
P/E Ratio1.5x
P/S RatioIs TCMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCMD income statement (TTM) | |
|---|---|
| Revenue | US$285.05m |
| Cost of Revenue | US$76.73m |
| Gross Profit | US$208.33m |
| Other Expenses | US$192.88m |
| Earnings | US$15.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 73.08% |
| Net Profit Margin | 5.42% |
| Debt/Equity Ratio | 12.9% |
How did TCMD perform over the long term?
See historical performance and comparison